Clinical Trials
38 trialsNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
I-SPY
QuantumLeap Healthcare Collaborative
DOSa
M.D. Anderson Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
ANGIO-TAX+
Centre Oscar Lambret
REGOSTA
Centre Leon Berard
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
M.D. Anderson Cancer Center
TAIS
Fudan University
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Massachusetts General Hospital
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Cemiplimab for Secondary Angiosarcomas
Radboud University Medical Center
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Propranolol in Angiosarcoma
The Netherlands Cancer Institute
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
OHSU Knight Cancer Institute
PROPANE
Herlev and Gentofte Hospital
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
EVA
Heidelberg University
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
VORTEX
Sheffield Teaching Hospitals NHS Foundation Trust
ASAP
Dong-A University Hospital
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Stanford University
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
University of Miami
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
UNICANCER
ANGIHE
Centre Oscar Lambret
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
Alliance for Clinical Trials in Oncology
PROPAN
Assistance Publique Hopitaux De Marseille
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
University of South Florida